NO20063843L - Polymorfe formar av en GABA-A-agonist - Google Patents

Polymorfe formar av en GABA-A-agonist

Info

Publication number
NO20063843L
NO20063843L NO20063843A NO20063843A NO20063843L NO 20063843 L NO20063843 L NO 20063843L NO 20063843 A NO20063843 A NO 20063843A NO 20063843 A NO20063843 A NO 20063843A NO 20063843 L NO20063843 L NO 20063843L
Authority
NO
Norway
Prior art keywords
gaba
agonist
polymorphic forms
new crystalline
anhydrates
Prior art date
Application number
NO20063843A
Other languages
English (en)
Inventor
Vincent Brett Cooper
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063843(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NO20063843L publication Critical patent/NO20063843L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

To nye, krystallinske mono-hydrater og to nye, krystallinske anhydrater av gaboksadol er beskrevet, sammen med fiemgangsmåter for fremstilling av disse.
NO20063843A 2004-01-30 2006-08-29 Polymorfe formar av en GABA-A-agonist NO20063843L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist
PCT/GB2005/000288 WO2005073237A2 (en) 2004-01-30 2005-01-28 Polymorphic forms of a gabaa agonist

Publications (1)

Publication Number Publication Date
NO20063843L true NO20063843L (no) 2006-08-29

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063843A NO20063843L (no) 2004-01-30 2006-08-29 Polymorfe formar av en GABA-A-agonist

Country Status (35)

Country Link
US (2) US7262300B2 (no)
EP (2) EP2042505A1 (no)
JP (1) JP4917440B2 (no)
KR (1) KR101210361B1 (no)
CN (1) CN1914212B (no)
AR (1) AR047511A1 (no)
AT (1) ATE414088T1 (no)
AU (1) AU2005209473B2 (no)
BR (1) BRPI0506858A (no)
CA (1) CA2554536C (no)
CO (1) CO5700743A2 (no)
CY (1) CY1108647T1 (no)
DE (1) DE602005010975D1 (no)
DK (1) DK1713813T3 (no)
DO (1) DOP2005000013A (no)
EA (1) EA009413B1 (no)
EC (1) ECSP066735A (no)
ES (1) ES2314613T3 (no)
GB (2) GB0402118D0 (no)
HK (1) HK1096547A1 (no)
HR (1) HRP20080614T3 (no)
IL (1) IL176863A0 (no)
MA (1) MA28364A1 (no)
MX (1) MXPA06008595A (no)
MY (1) MY139525A (no)
NO (1) NO20063843L (no)
NZ (1) NZ548191A (no)
PE (1) PE20050769A1 (no)
PL (1) PL1713813T3 (no)
PT (1) PT1713813E (no)
SI (1) SI1713813T1 (no)
TW (1) TWI345972B (no)
UA (1) UA87487C2 (no)
WO (1) WO2005073237A2 (no)
ZA (1) ZA200605307B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
WO2006083682A2 (en) 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
ES2524994T3 (es) 2005-09-28 2014-12-16 Auris Medical Ag Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
MX2018000745A (es) * 2015-07-17 2018-08-15 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
CA3032686A1 (en) * 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Use of ganaxolone for treating status epilepticus in a subject
EP3528807A4 (en) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
EP4051272A4 (en) 2019-12-18 2023-01-04 Ovid Therapeutics Inc. GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
CA3182508A1 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4315934A (en) * 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
WO2001022941A1 (en) 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
DE50205794D1 (de) 2001-05-18 2006-04-20 Lonza Ag Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
WO2002094225A1 (en) 2001-05-21 2002-11-28 H. Lundbeck A/S Granular preparations of gaboxadol
AU2002333157A1 (en) * 2002-09-03 2004-03-29 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
PT1641456E (pt) * 2003-06-25 2010-06-01 Lundbeck & Co As H Gaboxadol para o tratamento de depressão e outros distúrbios afectivos
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2008504306A (ja) 2004-06-29 2008-02-14 ハー・ルンドベック・アクチエゼルスカベット 神経因性疼痛、線維筋痛症または慢性関節リウマチの治療
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
WO2006083682A2 (en) 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
EP1863808A1 (en) 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
EP1906953A4 (en) 2005-04-29 2009-05-20 Lundbeck & Co As H FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL

Also Published As

Publication number Publication date
US20070259912A1 (en) 2007-11-08
CA2554536C (en) 2012-09-18
CO5700743A2 (es) 2006-11-30
MXPA06008595A (es) 2006-08-28
JP2007519697A (ja) 2007-07-19
AR047511A1 (es) 2006-01-25
US20050171142A1 (en) 2005-08-04
IL176863A0 (en) 2006-10-31
GB2410434A (en) 2005-08-03
DK1713813T3 (da) 2009-02-16
TW200534856A (en) 2005-11-01
EP1713813A2 (en) 2006-10-25
WO2005073237A2 (en) 2005-08-11
HK1096547A1 (en) 2007-06-01
PE20050769A1 (es) 2005-10-04
ECSP066735A (es) 2006-10-31
BRPI0506858A (pt) 2007-05-29
PT1713813E (pt) 2008-12-26
CN1914212A (zh) 2007-02-14
TWI345972B (en) 2011-08-01
NZ548191A (en) 2010-04-30
KR101210361B1 (ko) 2012-12-10
HRP20080614T3 (en) 2009-01-31
DE602005010975D1 (de) 2008-12-24
CY1108647T1 (el) 2014-04-09
UA87487C2 (ru) 2009-07-27
WO2005073237A3 (en) 2005-10-20
EA200601404A1 (ru) 2006-12-29
MY139525A (en) 2009-10-30
AU2005209473B2 (en) 2010-03-04
PL1713813T3 (pl) 2009-04-30
EP1713813B1 (en) 2008-11-12
DOP2005000013A (es) 2005-08-15
US8236958B2 (en) 2012-08-07
ZA200605307B (en) 2007-11-28
JP4917440B2 (ja) 2012-04-18
SI1713813T1 (sl) 2009-02-28
MA28364A1 (fr) 2006-12-01
AU2005209473A1 (en) 2005-08-11
GB0402118D0 (en) 2004-03-03
EA009413B1 (ru) 2007-12-28
ES2314613T3 (es) 2009-03-16
CN1914212B (zh) 2010-10-06
US7262300B2 (en) 2007-08-28
ATE414088T1 (de) 2008-11-15
EP2042505A1 (en) 2009-04-01
KR20070007070A (ko) 2007-01-12
CA2554536A1 (en) 2005-08-11
GB0501847D0 (en) 2005-03-09

Similar Documents

Publication Publication Date Title
NO20063843L (no) Polymorfe formar av en GABA-A-agonist
DK1888580T3 (da) Pyrido[2,3-D]pyrimidiner, der er egnede som HCV-hæmmere, og fremgangsmåde til fremstillingen af disse
SG156689A1 (en) Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate
EP1953542A4 (en) METHOD FOR QUANTITATING A MEMBRANE PROTEIN USING A MASS SPECTROMETER
SG148142A1 (en) Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof
NO20081926L (no) Oppslemmingsblanding og fremgangsmåter for fremstilling av denne
DK1984744T3 (da) Fremgangsmåder og sæt til diagnostisering af væksthormonmangel
ATE495162T1 (de) Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung
BRPI0903495A2 (pt) microorganismos mutantes com capacidade de produzir putrescina e método para produção de putrescina utilizando os mesmos
NO20065179L (no) Polysykliske pyridiner som kalsium-kanalmodulatorer
NO20050235D0 (no) System og fremgangsmate for produksjon til havs med bronnstyring
MX2009011255A (es) Proceso para preparar capecitabina.
DK1924585T3 (da) Hidtil ukendt krystallinsk for af et pyridazino[4,5-b]indol-derivat
DK1952103T3 (da) Fremgangsmåde til at veje med flere vejeceller
NO20051393L (no) Prosess og intermediater for fremstilling av tienopyrrol-derivater
ATE541853T1 (de) Tanaproget-derivate, metaboliten und verwendungen dafür
DK1735623T3 (da) Test til diagnosticering af infektion med mycobakterium tuberculosis
NI200800021A (es) Derivados de n - (arilalquil) - 1h - pirrolopiridin - 2 - carboxamidas, su preparación y su aplicación en terapéutica
WO2007075307A3 (en) Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemiacetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate
GT200500216A (es) Derivados de cci-779 y metodos para su preparacion
ATE458196T1 (de) Verfahren zum apoptosenachweis
NO20083269L (no) Prosess for a anvende krystallinsk orlistatmetoder
SG148168A1 (en) Genetically modified microorganism and process for production of macrolide compound using the microorganism
DE602006000227D1 (de) Elektrodensubstrat, Detektionsvorrichtung mit dem Substrat, Kit mit der Detektionsvorrichtung und Detektionsverfahren unter Verwendung des Kits
EA200800411A1 (ru) Новая кристаллическая форма периндоприлэрбумина

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application